Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Non-Current Deffered Revenue: 2011-2017

Historic Non-Current Deffered Revenue for EyePoint Pharmaceuticals (EYPT) over the last 7 years, with Dec 2017 value amounting to $42,000.

  • EyePoint Pharmaceuticals' Non-Current Deffered Revenue fell 26.32% to $42,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $42,000, marking a year-over-year decrease of 26.32%. This contributed to the annual value of $51,000 for FY2017, which is 99.09% down from last year.
  • EyePoint Pharmaceuticals' Non-Current Deffered Revenue amounted to $42,000 in Q4 2017, which was down 10.64% from $47,000 recorded in Q3 2017.
  • In the past 5 years, EyePoint Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $6.1 million in Q4 2013 and a low of $42,000 during Q4 2017.
  • Its 3-year average for Non-Current Deffered Revenue is $3.3 million, with a median of $5.6 million in 2016.
  • In the last 5 years, EyePoint Pharmaceuticals' Non-Current Deffered Revenue surged by 51.88% in 2013 and then plummeted by 99.16% in 2017.
  • EyePoint Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $6.1 million in 2013, then fell by 7.99% to $5.6 million in 2014, then remained steady at $5.6 million in 2015, then plummeted by 98.98% to $57,000 in 2016, then decreased by 26.32% to $42,000 in 2017.
  • Its Non-Current Deffered Revenue was $42,000 in Q4 2017, compared to $47,000 in Q3 2017 and $51,000 in Q2 2017.